Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.
The device, which is delivered transapically, represents an option for very sick patients who previously have had none.
Edwards Lifesciences (NYSE: EW) today shared new data demonstrating successful outcomes with its mitral and tricuspid ...
Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm ...
TipRanks on MSN
Edwards Lifesciences’ MITRIS Valve Study: A Potential Game-Changer in Mitral Valve Replacement
Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is conducting a study titled ...
Venus Medtech's Cardiovalve subsidiary announced today that it completed enrollment in a study of its tricuspid valve ...
Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences Corp. is conducting a ...
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch ...
A 79-year-old woman with severe heart failure and dual valve leakage underwent a rare, non-surgical double valve repair using ...
GlobalData on MSN
Nyra Medical commences trial of CARLEN system for FMR
The single-leaflet implant restores leaflet coaptation while maintaining the valve's natural movement and orifice space.
Dr. Eom and Director Lim from NEL Animal Medical Foundation were featured as speakers at the 5th Asian Small Animal ...
Edwards Lifesciences remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback